Single-day famciclovir for the treatment of genital herpes: Follow-up results of time to next recurrence and assessment of antiviral resistance

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 483-487

  Bodsworth, Neil ^a   Fife, Kenneth ^b   Koltun, William ^c   Tyring, Stephen ^d   Abudalu, Mohammed ^e   Prichard, Mark ^f   Hamed, Kamal ^a,g  

^a Taylor Square Private Clinic ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Medical Center for Clinical Research   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Clayton Research Institute   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug resistance; Famciclovir; Genital herpes; Single day therapy; Time to next recurrence

Indexed keywords

FAMCICLOVIR; PENCICLOVIR; VALACICLOVIR; 2 AMINOPURINE; ANTIVIRUS AGENT; DRUG DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENITAL HERPES; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; VIRUS CULTURE; ARTICLE; PATHOLOGY;

2-AMINOPURINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HERPES GENITALIS; HUMANS; RECURRENCE;

EID: 64249169947     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802664678     Document Type: Conference Paper

References (23)

1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296:964-973 (Pubitemid 44285373)
2. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002;186(Suppl):S3-28 (Pubitemid 35178845)
3. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;12:847-854
4. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204:595-603 (Pubitemid 46457082)
5. Brown ZA, Kern ER, Spruance SL, Overall Jr JC. Clinical and virologic course of herpes simplex genitalis. West J Med 1979;130:414-421 (Pubitemid 9216462)
6. Beauman JG. Genital herpes: a review. Am Fam Physician 2005;72:1527-1534 (Pubitemid 43093404)
7. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958-962 (Pubitemid 34229765)
8. Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944-948 (Pubitemid 34229763)
9. Bodsworth N, Bloch M, McNulty A, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sexual Health 2008;5:219-225
10. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double blind, placebo trial. Clin Infect Dis 2006;42:8-13 (Pubitemid 41832073)
11. Bavaro JB, Drolette L, Koelle DM, et al. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis 2008;35:383-386
12. Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47:651-658
13. Prichard MN, Keith KA, Johnson MP, et al. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother 2007;51:1795-1803 (Pubitemid 46744160)
14. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39(Suppl 5):S248-57 (Pubitemid 39447300)
15. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76-80 (Pubitemid 36091604)
16. Sarisky RT, Bacon TH, Boon RJ, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven trials. Arch Virol 2003;148:1757-1769 (Pubitemid 37144179)
17. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186(Suppl 1):S40-6 (Pubitemid 35178848)
18. Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994;169:1338-1341 (Pubitemid 24164601)
19. Kreisel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005;192:156-161 (Pubitemid 40863868)
20. Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16:114-128 (Pubitemid 36114710)
21. Pottage JC Jr, Kessler HA. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 1995;4:115-124
22. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993;37:2241-2243
23. Sarisky RT, Quail MR, Clark PE, et al. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001;75:1761-1769 (Pubitemid 32110165)